Leinco Technologies, Inc.

Leinco Technologies, Inc. is a specialized provider of high-quality antibodies and reagents for scientific research, focusing on applications related to cancer, infectious diseases, and immunology. Founded in 1992 and headquartered in St. Louis, US, Leinco Technologies, Inc.

specializes in developing antibodies and reagents for research use. The company had a significant transaction in November 2021 when Ampersand Capital Partners recapitalized Leinco for a majority stake, although financial details were not disclosed. W. Leinert serves as CEO, overseeing operations since the company's establishment.

Leinco Technologies specializes in providing high-quality antibodies and reagents for research applications, emphasizing biosimilars, secondary and primary antibodies, immunohistochemistry (IHC) antibodies, and ultra-pure recombinant proteins. Their product offerings are designed to support various scientific investigations, particularly in the fields of cancer, infectious diseases, and immunology. Leinco’s antibodies are validated for use in diverse applications, including Western blotting, ELISA, and flow cytometry, catering to a wide customer base that includes academic researchers, biopharmaceutical companies, and diagnostic laboratories. The company’s products are marketed globally, with a notable presence in North America, Europe, and Asia, providing researchers with reliable tools to generate reproducible data for peer-reviewed publications.

Leinco Technologies generates revenue through direct sales of its antibody and reagent products to a varied clientele, which includes research institutions and pharmaceutical companies. The transaction structure encompasses direct to consumer sales, primarily focused on B2B engagements, where customers place orders for individual products or bulk quantities based on their specific research needs. Pricing for products like the mAbMods™ Anti-Mouse TREM2 and other specialized antibodies ranges significantly, reflecting their high quality and performance. This pricing model supports the company's focus on high-value, specialized research products, fostering long-term relationships with clients by meeting their demanding scientific requirements.

Following the recapitalization in November 2021, Leinco Technologies plans to expand its manufacturing production capacity, scientific capabilities, and product offerings. The company is targeting international growth, with specific plans to enhance its presence in emerging markets within Europe and Asia. Recent funding will be directed towards these growth initiatives, supporting the development of new products designed for various research applications.